Ownership and insider activity for Protalix BioTherapeutics, Inc. (PLX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Price
| Price | $2.68 |
| Market Cap | $216M |
| Exchange | AMEX |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-03 | Schwartz Aharon | A-Award | 17,000 | $44K |
| 2026-09-03 | Schwartz Aharon | A-Award | 8,500 | |
| 2026-09-03 | Naos Yaron | A-Award | 112,000 | $290K |
| 2026-09-03 | Naos Yaron | A-Award | 56,000 | |
| 2026-09-03 | Melincoff Gwen A | A-Award | 17,000 | $44K |
| 2026-09-03 | Elze Christian | A-Award | 17,000 | $44K |
| 2026-09-03 | Elze Christian | A-Award | 8,500 | |
| 2026-09-03 | Melincoff Gwen A | A-Award | 8,500 | |
| 2026-09-03 | Boudes Pol F | A-Award | 17,000 | $44K |
| 2026-09-03 | Boudes Pol F | A-Award | 8,500 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63.3M | $51.2M | $37.8M | $17.8M | $18.3M | $39.0M | $17.1M | $23.6M | $19.8M | $14.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | $20.3M | 0 | $5.1M | $20.9M | $15.1M | $15.6M |
| Receivables | $693000 | $1.7M | $4.7M | $4.7M | $2.0M | $3.4M | $4.6M | $5.3M | $2.9M | $8.8M |
| Inventory | $5.2M | $7.8M | $8.6M | $8.2M | $13.1M | $18.0M | $16.8M | $19.0M | $21.2M | $25.7M |
| Total Current Assets | $71.9M | $62.7M | $53.0M | $32.5M | $55.7M | $61.7M | $44.9M | $69.9M | $60.1M | $66.7M |
| Property, Plant & Equipment | $8.7M | $7.7M | $6.4M | $10.9M | $10.4M | $9.9M | $9.6M | $10.9M | $10.0M | $12.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $82.2M | $72.2M | $61.1M | $45.4M | $67.9M | $73.7M | $55.8M | $84.4M | $73.4M | $82.3M |
| Accounts Payable | $4.0M | $7.5M | $5.2M | $6.5M | $7.2M | $7.0M | $5.9M | $4.3M | $4.5M | $5.3M |
| Short-term Debt | $53.9M | $5.9M | 0 | $4.3M | $58.5M | 0 | 0 | $21.7M | 0 | 0 |
| Total Current Liabilities | $66.2M | $22.8M | $25.4M | $40.2M | $86.5M | $33.2M | $32.4M | $45.5M | $25.6M | $26.5M |
| Long-term Debt | $23.6M | $46.3M | $48.0M | $51.0M | 0 | $27.9M | $28.2M | 0 | 0 | 0 |
| Total Liabilities | $92.2M | $103.5M | $114.0M | $115.7M | $95.0M | $79.7M | $66.4M | $50.9M | $30.2M | $34.1M |
| Retained Earnings | -$212.7M | -$297.9M | -$322.6M | -$340.8M | -$347.4M | -$374.9M | -$389.9M | -$381.5M | -$378.4M | -$385.0M |
| Total Equity | -$10.0M | -$31.3M | -$52.9M | -$70.3M | -$27.0M | -$6.0M | -$10.6M | $33.6M | $43.2M | $48.2M |
| Total Debt | $77.5M | $52.2M | $48.0M | $60.9M | $64.4M | $33.5M | $33.5M | $27.7M | $5.5M | $8.3M |
| Net Debt | $14.2M | $1.0M | $10.2M | $43.1M | $25.9M | -$5.5M | $11.3M | -$16.9M | -$29.3M | -$22.0M |
| Working Capital | $5.7M | $39.9M | $27.6M | -$7.7M | -$30.8M | $28.5M | $12.5M | $24.4M | $34.5M | $40.2M |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 2.94 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -3.05 |
Profitability
| Return on Equity | 31.61% |
| Return on Invested Capital | 23.33% |
| Return on Assets | 17.17% |
| Gross Margin | 69.20% |
| Operating Margin | 28.89% |
| Net Margin | 23.50% |
Related companies: CDXS · CHRS · GNFT · IVVD · MDWD · NTHI · OABI
Explore sector: Healthcare · Biotechnology
More sections of PLX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks